Tome Biosciences to Acquire Replace Therapeutics for ~$185M
Shots:
- Tome expects to acquire Replace for its novel PGI method that allows insertion & deletion of small DNA sequences. Earlier Replace was a part of Rewrite Therapeutics, acquired by Intellia Therapeutics
- Under the terms of the agreement, Tome will acquire Replace through a merger transaction of $65M in up front & near-term milestone payments totaling the deal value to $185M through a mix of stock & cash
- Complementing Tome's DNA PGI technology, integrase-mediated PGI (I-PGI), Replace's PGI technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences as the ligase-mediated PGI (L-PGI) technology is well-suited for 10s to 100s of base pair DNA edits
Ref: Tome Biosciences | Image: Tome Biosciences
Related News:- Athenex to Acquire Kuur Therapeutics for ~$185M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
